Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PEPD | P12955 | 2/20 | 0.40 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109077 | 1.00 | POLB (0.49) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| SCHEMBL200913 | 1.00 | POLB (0.49) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| Hydrochloric Acid SCHEMBL3055388 | 0.98 | POLB (0.47) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| Hydrochloric Acid SCHEMBL2337448 | 0.98 | POLB (0.47) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| Hydrochloric Acid SCHEMBL5159954 | 0.98 | POLB (0.47) | POLBFKBP1ASMN1; SMN2PEPDXPNPEP1 | |
| SCHEMBL28937243 | 0.94 | FKBP1A (0.49) | POLBFKBP1ASMN1; SMN2TP53MMP2 | |
| SCHEMBL21616613 | 0.94 | FKBP1A (0.49) | POLBFKBP1ASMN1; SMN2TP53MMP2 | |
| SCHEMBL8385960 | 0.80 | POLB (0.36) | POLB | |
| SCHEMBL678254 | 0.80 | POLB (0.36) | POLB | |
| SCHEMBL14048826 | 0.79 | POLB (0.32) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924139-A | Amplifying synthesis method of Fmoc-Hyp (tBu) -OH | 康化（上海）新药研发有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-104844495-A | Synthesis method of (2S,4S)-4-thiophenyl-L-proline hydrochloride | UNIV WUHAN TECH | 2015-08-19 | — | — | CN | claimed |
| JP-7126247-A | — | — | None | — | — | JP | disclosed |
| CN-117924139-A | Amplifying synthesis method of Fmoc-Hyp (tBu) -OH | 康化（上海）新药研发有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-116239591-A | (4R) -sulfonamido-L-prolinamide compound, preparation method, application and pharmaceutical composition thereof | 嘉兴学院 | 2023-06-09 | — | — | CN | disclosed |
| CN-105142727-B | Enoxolone Asia amide groups hydroxyproline Arrcostab and its shielded derivative | 露华浓消费产品公司 | 2018-09-04 | — | — | CN | disclosed |
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3057926-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | Merck Sharp & Dohme Corp. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-5670515-A | TREATMENT OF THROMBOSIS, STROKE, CARDIAC INFARCT, INFLAMMATION, AND ARTERIOSCLEROSIS; ANTITUMOR AGENTS, WOUND HEALING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5658928-A | ANTICOAGULANTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS,WOUND HEALING AGENTS, OSTEOPOROSIS | HOFFMANN-LA ROCHE INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5623049-A | FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| US-5545658-A | FOR TREATMENT OR PROPHYLAXIS OF ILLNESSES WHICH ARE CAUSED BY THE BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELETS AND BY BLOOD PLATELET AGGREGATION AND CELL-CELL ADHESION | HOFFMAN-LA ROCHE INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0505868-B1 | N-Acyl-alpha-aminoacids derivatives | HOFFMANN LA ROCHE (CH) | 1995-09-13 | — | — | EP | disclosed |
| JP-H07126247-A | NEUTRALIZATION OF SALT OF CYCLIC IMINO ACID ESTER | TOKUYAMA CORP | 1995-05-16 | — | — | JP | disclosed |
| US-5378712-A | Antithrombosis | Hoffmann-La Roche Inc (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | disclosed |
| US-4329473-A | HYPOTENSIVE AGENTS | SRI INTERNATIONAL | 1982-05-11 | — | — | US | disclosed |